The Hyderabad-based company's share closed at Rs 2,329.80 after gaining 2.80 per cent. In intra day, it had surged over 3 per cent to touch a high of Rs 2,335.
Similarly on NSE, the stock climbed as much as 2.69 per cent to end at Rs 2,330.10. During the trading session, the stock had touched a high Rs 2,335 and a low of Rs 2,281.95.
In terms of volume, 61,000 shares were traded on BSE and nearly 7.30 lakh shares changed hands on NSE.
Briviact (brivaracetam) is approved as an adjunctive therapy for the treatment of partial-onset seizures in epilepsy patients who are 16 years of age and older.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)